Imaan Bayoumi1, Mosab Al Balas2, Steven M Handler3, Lisa Dolovich4, Brian Hutchison5, Anne Holbrook6. 1. Department of Family Medicine, McMaster University, Canada; Kingston Community Health Centres, Canada; Department of Family Medicine, Queen's University, Canada. Electronic address: imaan@kchc.ca. 2. Department of Pharmacy, St. Joseph's Health Care Hamilton, Hamilton, Canada. 3. Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States; Division of Geriatric Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States; Geriatric Research Education and Clinical Center (GRECC), Veterans Affairs Pittsburgh Healthcare System (VAPHS), Pittsburgh, PA, United States; Center for Health Equity Research and Promotion (CHERP), VAPHS, Pittsburgh, PA, United States. 4. Department of Clinical Epidemiology and Biostatistics, McMaster University, Canada; Department of Family Medicine, McMaster University, Canada; Centre for Evaluation of Medicines, St. Joseph's Healthcare Hamilton, Canada. 5. Department of Clinical Epidemiology and Biostatistics, McMaster University, Canada; Department of Family Medicine, McMaster University, Canada. 6. Department of Clinical Epidemiology and Biostatistics, McMaster University, Canada; Division of Clinical Pharmacology & Therapeutics, Department of Medicine, McMaster University, Canada; Centre for Evaluation of Medicines, St. Joseph's Healthcare Hamilton, Canada.
Abstract
BACKGROUND: Inadequate lab monitoring of drugs is a potential cause of ADEs (adverse drug events) which is remediable. OBJECTIVES: To determine the effectiveness of computerized drug-lab alerts to improve medication-related outcomes. DATA SOURCES: Citations from the Computerized Clinical Decision Support System Systematic Review (CCDSSR) and MMIT (Medications Management through Health Information Technology) databases, which had searched MEDLINE, EMBASE, CINAHL, Cochrane Database of Systematic Reviews, International Pharmaceutical Abstracts from 1974 to March 27, 2013. STUDY SELECTION: Randomized controlled trials (RCTs) of clinician-targeted computerized drug lab alerts conducted in any healthcare setting. Two reviewers performed full text review to determine study eligibility. DATA ABSTRACTION: A single reviewer abstracted data and evaluated validity of included studies using Cochrane handbook domains. DATA SYNTHESIS: Thirty-six studies met the inclusion criteria (25 single drug studies with 22,504 participants, 14 targeting anticoagulation; 11 multi-drug studies with 56,769 participants). ADEs were reported as an outcome in only four trials, all targeting anticoagulants. Computerized drug-lab alerts did not reduce ADEs (OR 0.89, 95% CI 0.79-1.00, p=0.05), length of hospital stay (SMD 0.00, 95%CI -0.93 to 0.93, p=0.055, 1 study), likelihood of hypoglycemia (OR 1.29, 95% CI 0.31-5.37) or likelihood of bleeding, but were associated with increased likelihood of prescribing changes (OR 1.73, 95% CI 1.21-2.47) or lab monitoring (OR 1.47, 95% confidence interval 1.12-1.94) in accordance with the alert. CONCLUSIONS: There is no evidence that computerized drug-lab alerts are associated with important clinical benefits, but there is evidence of improvement in selected clinical surrogate outcomes (time in therapeutic range for vitamin K antagonists), and changes in process outcomes (lab monitoring and prescribing decisions).
BACKGROUND: Inadequate lab monitoring of drugs is a potential cause of ADEs (adverse drug events) which is remediable. OBJECTIVES: To determine the effectiveness of computerized drug-lab alerts to improve medication-related outcomes. DATA SOURCES: Citations from the Computerized Clinical Decision Support System Systematic Review (CCDSSR) and MMIT (Medications Management through Health Information Technology) databases, which had searched MEDLINE, EMBASE, CINAHL, Cochrane Database of Systematic Reviews, International Pharmaceutical Abstracts from 1974 to March 27, 2013. STUDY SELECTION: Randomized controlled trials (RCTs) of clinician-targeted computerized drug lab alerts conducted in any healthcare setting. Two reviewers performed full text review to determine study eligibility. DATA ABSTRACTION: A single reviewer abstracted data and evaluated validity of included studies using Cochrane handbook domains. DATA SYNTHESIS: Thirty-six studies met the inclusion criteria (25 single drug studies with 22,504 participants, 14 targeting anticoagulation; 11 multi-drug studies with 56,769 participants). ADEs were reported as an outcome in only four trials, all targeting anticoagulants. Computerized drug-lab alerts did not reduce ADEs (OR 0.89, 95% CI 0.79-1.00, p=0.05), length of hospital stay (SMD 0.00, 95%CI -0.93 to 0.93, p=0.055, 1 study), likelihood of hypoglycemia (OR 1.29, 95% CI 0.31-5.37) or likelihood of bleeding, but were associated with increased likelihood of prescribing changes (OR 1.73, 95% CI 1.21-2.47) or lab monitoring (OR 1.47, 95% confidence interval 1.12-1.94) in accordance with the alert. CONCLUSIONS: There is no evidence that computerized drug-lab alerts are associated with important clinical benefits, but there is evidence of improvement in selected clinical surrogate outcomes (time in therapeutic range for vitamin K antagonists), and changes in process outcomes (lab monitoring and prescribing decisions).
Authors: Jacqueline M Bos; Patricia M L A van den Bemt; Wietske Kievit; Johan L W Pot; J Elsbeth Nagtegaal; André Wieringa; Monique M L van der Westerlaken; Gert Jan van der Wilt; Peter A G M de Smet; Cornelis Kramers Journal: Br J Clin Pharmacol Date: 2016-11-10 Impact factor: 4.335
Authors: Francesc Saigí-Rubió; José Juan Pereyra-Rodríguez; Joan Torrent-Sellens; Hans Eguia; Natasha Azzopardi-Muscat; David Novillo-Ortiz Journal: Int J Environ Res Public Health Date: 2021-04-27 Impact factor: 3.390